Dr. Liu on Medical Advancements for Neuroendocrine Tumors

Eric Liu, MD, FACS
Published: Friday, Oct 16, 2015



Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors (NETs).

Somatostatin analogs, a synthetic hormone therapy, have been a standard treatment for NETs, Liu explains, while a new somatostatin analog, somatuline, has also been shown to slow tumor growth. Additional recently approved agents for pancreatic NETS include sunitinib and everolimus.

Liu mentions other agents that are pushing the field forward, including telotristat etiprate for the treatment of carcinoid syndrome, and Lutathera, described as a radioactive version of octreotide, also shown to slow tumor growth.

<<< View more from the 2015 NANETS Symposium



Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors (NETs).

Somatostatin analogs, a synthetic hormone therapy, have been a standard treatment for NETs, Liu explains, while a new somatostatin analog, somatuline, has also been shown to slow tumor growth. Additional recently approved agents for pancreatic NETS include sunitinib and everolimus.

Liu mentions other agents that are pushing the field forward, including telotristat etiprate for the treatment of carcinoid syndrome, and Lutathera, described as a radioactive version of octreotide, also shown to slow tumor growth.

<<< View more from the 2015 NANETS Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x